DataMeds AI extinguishes approximately $19M liability

The settlement extinguished approximately $19 million in balance-sheet liability, while a separate platform license involved issuance of 666,667 common shares.

Rhea-AI Filing Summary

DataMeds AI, Inc. entered a settlement agreement and release and paid $450,000: $350,000 was aggregate consideration for repurchasing and extinguishing 364,099 common shares, and $100,000 was for the compromise and settlement of the MIPA and other released claims. The agreement extinguished approximately $19 million in liability shown on the company’s consolidated balance sheet.

DataMeds stated that its stockholders’ equity was greater than $2,500,000 as of October 13, 2026, and that the transactions increased equity. Separately, on October 13, 2026, it licensed a care management platform from REBOOT Health AI, Inc. for integration into its business model and issued REBOOT 666,667 common shares.

1 point · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Major pointApproximately $19 million in balance-sheet liability extinguished. 1.9× market cap

Negative

• None.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Stockholders’ equity: Greater than $2,500,000 Settlement payment: $450,000 Share repurchase consideration: $350,000 +4 more

7 metrics

Stockholders’ equity Greater than $2,500,000 As of October 13, 2026

Settlement payment $450,000 Paid under the settlement agreement

Share repurchase consideration $350,000 Aggregate consideration for repurchase and extinguishment of common shares

Common shares repurchased and extinguished 364,099 shares Under the settlement agreement

Compromise and settlement consideration $100,000 For settlement of the MIPA and other released claims

Balance-sheet liability extinguished Approximately $19 million Liability shown on the consolidated balance sheet

Common shares issued to REBOOT 666,667 shares In connection with the care management platform license

Key Terms

stockholders’ equity, aggregate consideration, consolidated balance sheet

3 terms

stockholders’ equity financial

"stockholders’ equity is greater than $2,500,000"

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

aggregate consideration financial

"$350,000 as aggregate consideration"

consolidated balance sheet financial

"appears on the Company’s consolidated balance sheet"

A consolidated balance sheet shows the combined financial position of a parent company and all of its controlled subsidiaries as if they were one single business, listing total assets, liabilities and shareholders’ equity. For investors, it matters because it gives a full-picture view of the group’s resources and obligations—like looking at a family’s joint bank account instead of each member’s separate accounts—so you can judge overall strength, leverage and risk without being misled by internal transfers between units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much liability did MEDS extinguish in its settlement?

DataMeds extinguished approximately $19 million in liability shown on its consolidated balance sheet. The company paid $450,000 under the settlement, including $350,000 for 364,099 shares and $100,000 for settlement of the MIPA and other released claims.

How many shares did MEDS issue to REBOOT alongside the platform license?

DataMeds issued 666,667 common shares to REBOOT Health AI, Inc. after licensing a care management platform for integration into its business model.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 05:27 PM EDT Accepted by SEC EDGAR 10/13/2026 - 05:27 PM EDT Learn about SEC filing dates

false 0002030763 0002030763 2026-10-13 2026-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): October 13, 2026

DATAMEDS AI, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42530		93-3264234
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Bayport Drive, Suite 950, Tampa, FL		33607
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: 844-203-6092

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		MEDS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As of October 13, 2026, DataMEDS AI, Inc. (the “Company”) confirms that its stockholders’ equity is greater than $2,500,000. The transactions below resulted in the increase to the Company’s stockholders’ equity.

On September 11, 2026, the Company entered into a settlement agreement and release (the “Agreement”) with Brian Norton, individually and as Seller Representative (“Norton”), Tony Madsen, Mark DiSiena, T. Scott Madsen, Stephen J. Madsen, RxERP, Inc. d/b/a RxERP, Nomad Capital LLC (“Nomad”) and Strategix Global LLC (“Strategix”) (collectively, the “Settling Parties”). Norton, Nomad and Strategix are collectively the “Selling Holders.” The Company had previously filed an action against Norton, Tony Madsen, Mark DiSiena, RxERP and Nomad in state court in Florida and Brian Norton, individually and as Seller Representative, Strategix and Nomad previously had filed an action against the Company in the Court of Chancery in Delaware. Both actions concerned, among other matters, the Membership Interest Purchase Agreement dated May 11, 2023, as amended (the “MIPA”), the consideration and obligations alleged to arise under it and Company shares of common stock held by certain holders.

Pursuant to the Agreement, the Company has paid $450,000, with $350,000 attributed as aggregate consideration for the Company’s repurchase and extinguishment of of 364,099 shares of Common Stock and $100,000 as consideration for the compromise and settlement of the MIPA and all other released claims.

As a result of the Agreement, the Company extinguished approximately $19 million in liability that appears on the Company’s consolidated balance sheet.

In addition, on October 13, 2026, the Company entered into a license agreement with REBOOT Health AI, Inc. (“REBOOT”) pursuant to which the Company licensed a care management platform to integrate into its business model. Pursuant to the Agreement, the Company issued 666,667 shares of common stock to REBOOT.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DataMeds AI, Inc.
Date: October 13, 2026	By:	/s/ Prashant Patel
		Prashant Patel, President

-3-

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB